// App-Quantinova.ai

TPS9592 : A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.

Researchers

Presenter

  • Alexander Christopher Jonathan Van Akkooi

Principal Investigators

  • Paolo Antonio Ascierto

  • Paul D. Nathan

  • Paul Nghiem

  • Philip Reimann

  • Frank Hermann

  • Jrgen C. Becker

Medical Centers

  • Department of Pathology, the Netherlands Cancer Institute, Amsterdam, Netherlands

  • Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, 4SC AG, Planegg-Martinsried, Germany

  • Translational Skin Cancer Research, Deutsches Konsortium fur Translationale Krebsforschung (DKTK), Essen, Germany

Locations

  • Netherlands

  • Italy

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Merkel cell carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Avelumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04393753

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved